Preclinical assets still command this upfront payment

Preclinical licensing deals demonstrate that innovative science commands value even before clinical validation. Platform technologies, novel mechanisms, and hot therapeutic areas drive competitive dynamics that push preclinical deal terms well above historical norms. Total deal values can reach $504M.

Based on analysis of 600+ biopharma licensing deals from 2020-2026